Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 16:7:227-35.
doi: 10.2147/IJGM.S61297. eCollection 2014.

Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis

Margaret Noyes Essex  1 , Regina Behar  1 , Michael A O'Connell  1 , Pritha Bhadra Brown  1
Affiliations

Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis

Margaret Noyes Essex et al. Int J Gen Med. .

Abstract

Background: Celecoxib is an effective treatment for osteoarthritis (OA). However, information on its efficacy and safety profile in different racial/ethnic groups is limited. Noticeable differences among racial groups are found in other disease states, but a thorough investigation of OA is lacking. The objective of this study was to determine if celecoxib 200 mg once daily is as effective as naproxen 500 mg twice daily in the treatment of OA of the knee in Hispanic patients.

Methods: Hispanic patients aged ≥45 years with knee OA were randomized to receive celecoxib 200 mg once daily, naproxen 500 mg twice daily, or placebo for 6 weeks. The primary efficacy variable was the change in Patient's Assessment of Arthritis Pain at 6 weeks compared with baseline. Secondary variables were change in Patient's and Physician's Global Assessments of Arthritis from baseline to week 6/early termination, change in Western Ontario and McMaster Universities OA Index (WOMAC) from baseline to week 6/early termination, change in American Pain Society pain score, Pain Satisfaction Scale, Patient Health Questionnaire (PHQ-9), and measurements of upper gastrointestinal tolerability.

Results: In total, 239 patients completed the trial (96 celecoxib, 96 naproxen, 47 placebo). Celecoxib was as effective as naproxen in reducing OA pain (least squares mean change from baseline [standard error] -39.7 [2.7] for celecoxib and -36.9 [2.6] for naproxen). Patient's and Physician's Global Assessments of Arthritis, WOMAC scores, upper gastrointestinal tolerability, Pain Satisfaction Scale, and PHQ-9 showed no statistically significant differences between the celecoxib and naproxen groups. The incidence of adverse events and treatment-related adverse events were similar among the treatment groups.

Conclusion: Celecoxib 200 mg once daily was as effective as naproxen 500 mg twice daily in the treatment of signs and symptoms of knee OA in Hispanic patients. Celecoxib was shown to be safe and well tolerated in this patient population.

Keywords: cyclo-oxygenase-2; ethnicity; nonsteroidal anti-inflammatory drugs; race.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition. Notes: aIncludes “lost to follow-up” and “patient no longer willing to participate”; bincludes “protocol violation”. Abbreviations: AE, adverse events; mITT, modified intent-to-treat; qd, once daily; bid, twice daily.
Figure 2
Figure 2
Patient’s Global Assessment of Arthritis: modified intent-to-treat population. Abbreviations: qd, once daily; bid, twice daily.
Figure 3
Figure 3
Physician’s Global Assessment of Arthritis: overall ratings (modified intent-to-treat population). Abbreviations: qd, once daily; bid, twice daily.
See this image and copyright information in PMC

References

    1. United States Census Bureau US census bureau projections show a slower growing, older, more diverse nation a half century from now. US Department of Commerce; [Accessed October 22, 2013]. Available from: https://www.census.gov/newsroom/releases/archives/population/cb12-243.html.
    1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35. - PMC - PubMed
    1. Centers for Disease Control and Prevention Prevalence of doctor-diagnosed arthritis-attributable effects among Hispanic adults, by Hispanic subgroup – United States, 2002, 2003, 2006, and 2009. MMWR Morb Mortal Wkly Rep. 2011;60(6):167–171. - PubMed
    1. Centers for Disease Control and Prevention Racial/ethnic differences in the prevalence and impact of doctor-diagnosed arthritis – United States, 2002. MMWR Morb Mortal Wkly Rep. 2005;54(5):119–123. - PubMed
    1. Losina E, Walensky RP, Reichmann WM, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med. 2011;154(4):217–226. - PMC - PubMed

LinkOut - more resources